First-in-human randomized double-blind placebo-controlled single and multiple ascending dose study of MET409 in healthy men

Phase 1, randomised, double-blind trial of omesdafexor in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Metacrine, Inc. Primary endpoints: Safety and tolerability of single and multiple oral doses of MET409 and Pharmacokinetics of single and multiple oral doses of MET409. Started May 2018; status: active, not recruiting.